Harrow announced the successful manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA-approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. Harrow also announced that the second and third required PPQ batches are now scheduled; and should these PPQ batches meet specifications, the new TRIESENCE production process will be deemed complete, allowing Harrow to relaunch during 2024. TRIESENCE has been on the FDA Drug Shortage List for over five years with all TRIESENCE inventories having been depleted in the U.S. market for over two years.

Harrow remains committed to making TRIESENCE available to U.S. ophthalmologists and retina specialists.